Amarin’s Vascepa Will Get Two FDA Decisions, But Is That Good News?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA changes its mind and agrees to review appeal of ANCHOR special protocol assessment rescission, but that doesn’t necessarily mean an ultimate sNDA approval is any more likely.